Claims for Patent: 8,309,356

Summary for Patent: 8,309,356

Title:	Pseudocomplementary oligonucleotides for targeted gene therapy
Abstract:	Compositions and methods for targeted gene therapy are disclosed. Compositions containing double duplex-forming pseudocomplementary oligonucleotides are administered in combination with a donor oligonucleotide that is homologous to a target sequence on a double-stranded DNA molecule in need of repair or replacement. By activating cellular mechanisms involved in DNA synthesis, repair and recombination, the double duplex-forming pseudocomplementary oligonucleotides can introduce one or more mutations at a site of interest by increasing the efficiency of targeted recombination of the donor oligonucleotide. The pseudocomplementary oligonucleotides/donor oligonucleotide compositions may be administered in combination with a second therapeutic agent that enhances access of the pseudocomplementary oligonucleotides and/or the donor oligonucleotide to the target site, an agent that enhances or increases DNA repair or recombination, or an agent that enhances uptake or delivery of the oligonucleotides.
Inventor(s):	Glazer; Peter M. (Gulford, CT)
Assignee:	Yale University (New Haven, CT)
Application Number:	12/753,016
Patent Claims:	1. A recombinagenic or mutagenic composition comprising a pair of pseudocomplementary oligonucleotides having sequences that form a double duplex nucleic acid molecule with a target sequence of a double-stranded nucleic acid molecule, and a donor oligonucleotide essentially complementary to a recombination target sequence of the double-stranded nucleic acid molecule wherein the pair of pseudocomplementary oligonucleotides increase recombination of the donor oligonucleotide with the recombination target sequence compared to the donor oligonucleotide alone. 2. The composition of claim 1 wherein the donor oligonucleotide is single stranded. 3. The composition of claim 2 wherein the donor oligonucleotide is between 8 and 75 nucleotide residues in length. 4. The composition of claim 2 wherein the donor oligonucleotide contains one or more insertions, deletions, or substitutions relative to the recombination target sequence. 5. The composition of claim 1 wherein each of the pseudocomplementary oligonucleotides comprise between about 8 and 50 nucleobases. 6. The composition of claim 1 wherein the pseudocomplementary oligonucleotides and the donor oligonucleotide bind the double-stranded nucleic acid molecule at a distance of between about 25 and 75 nucleobases from each other. 7. The composition of claim 1 wherein the recombination target sequence of the double-stranded nucleic acid molecule is selected from the group consisting of a genomic DNA, a coding DNA sequence of a gene, an intron, a promoter, or an enhancer. 8. The composition of claim 7 wherein the gene is selected from the group consisting of an oncogene, a defective gene, and a viral gene. 9. The composition of claim 8 wherein the defective gene is selected from the group consisting of a defective .beta.-hemoglobin gene, a cystic fibrosis gene, and a hemophilia gene. 10. The composition of claim 1 wherein the pseudocomplementary oligonucleotides are pseudocomplemetary peptide nucleic acids (pcPNAs) and the donor oligonucleotide is DNA. 11. The composition of claim 10 wherein the pcPNAs are synthesized with 2,6-diaminopurine (D) and 2-thiouracil (sU) nucleobases instead of adenines (A) and thymine (T). 12. A method for targeted recombination or mutation of a nucleic acid molecule comprising administering to cells or an individual an effective amount of a pharmaceutically acceptable therapeutic composition comprising a pair of pseudocomplementary oligonucleotides having a sequence that forms a double duplex nucleic acid molecule with a target sequence of double-stranded nucleic acid molecule, and a donor oligonucleotide essentially complementary to a recombination target sequence of the double-stranded nucleic acid molecule wherein the pair of pseudocomplementary oligonucleotides increase recombination of the donor oligonucleotide with the recombination target sequence compared to the donor oligonucleotide alone. 13. The method of claim 12 wherein the donor oligonucleotide is a single strand of DNA between 8 and 75 nucleotide residues in length. 14. The method of claim 13 wherein the donor oligonucleotide contains one or more insertions, deletions, or substitutions relative to the recombination target sequence. 15. The method of claim 12 wherein the pseudocomplementary oligonucleotides and the donor oligonucleotide bind the double-stranded nucleic acid molecule at a distance of between about 25 and 75 nucleobases from each other. 16. The method of claim 12 wherein the recombination target sequence of the double-stranded nucleic acid molecule is selected from the group consisting of a genomic DNA, a coding DNA sequence of a gene, an intron, a promoter, or an enhancer. 17. The method of claim 16 wherein the gene is selected from the group consisting of an oncogene, a defective gene, and a viral gene. 18. The method of claim 17 wherein the gene is selected from the group consisting of a defective .beta.-hemoglobin gene, a cystic fibrosis gene, and a hemophilia gene. 19. The method of claim 12 wherein the pseudocomplementary oligonucleotides are pseudocomplemetary peptide nucleic acids (pcPNAs) comprising between about 8 and 50 nucleobases. 20. The method of claim 19 wherein the pcPNAs are synthesized with 2,6-diaminopurine (D) and 2-thiouracil (sU) nucleobases instead of adenines (A) and thymine (T). 21. The method of claim 12 further comprising co-administration of a second therapeutic agent selected from the group consisting of a histone deacetylase (HDAC) inhibitors and lysosomotropic agents.

Details for Patent 8,309,356

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-04-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-04-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-04-01